drugset / Trial / NCT01997164
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The primary objective of the study is to investigate the safety and tolerability of intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with neovascular age-related macular degeneration (AMD), and separately in patients with diabetic macular edema (DME).
Timeline
- Start
- 2014-11
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REGN910-3 | Unknown | — | Intravitreal |
| Subject | nesvacumab | Monoclonal antibody | — | Intravitreal |
| Background | Aflibercept | Protein / enzyme biologic | — | Intravitreal |